UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

13883 Maintenance of response through 136 weeks of long-term continuous risankizumab treatment: An analysis of patients from UltIMMa-1 and UltIMMa-2

Journal of the American Academy of Dermatology, 2020-12, Vol.83 (6), p.AB14-AB14

2020

Volltextzugriff (PDF)

15350 Consistent scalp psoriasis clearance with mirikizumab maintenance treatment at 104 weeks in patients who had less than PASI 90 response at week 16: A phase 2 study analysis

Journal of the American Academy of Dermatology, 2020-12, Vol.83 (6), p.AB148-AB148

2020

Volltextzugriff (PDF)

15984 Psoriasis patients treated with ixekizumab were maintained longer on monotherapy compared with other biologics in real-world clinical practice settings: Results from IBM MarketScan databases

Journal of the American Academy of Dermatology, 2020-12, Vol.83 (6), p.AB52-AB52

2020

Volltextzugriff (PDF)

16007 Ixekizumab demonstrated longer medication persistence than other biologics in the treatment of psoriasis patients: Results from IBM MarketScan databases

Journal of the American Academy of Dermatology, 2020-12, Vol.83 (6), p.AB168-AB168

2020

Volltextzugriff (PDF)

A 52-week, open-label study of the efficacy and safety of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with chronic plaque psoriasis

Journal of the American Academy of Dermatology, 2014-12, Vol.71 (6), p.1176-1182

2014

Volltextzugriff (PDF)

Absence of Borrelia burgdorferi in patients with localized scleroderma (morphea)

Journal of the American Academy of Dermatology, 1995-10, Vol.33 (4), p.682-684

1995

Volltextzugriff (PDF)

Absence of human papillomavirus infection in cutaneous lichen planus

Journal of the American Academy of Dermatology, 1997-02, Vol.36 (2), p.267-268

1997

Volltextzugriff (PDF)

ACROKERATOELASTOIDOSIS OF COSTA

International journal of dermatology, 1995-06, Vol.34 (6), p.431-433

1995

Volltextzugriff (PDF)

Acute Papulosquamous Eruption of the Extremities Demonstrating an Isomorphic Response

Archives of dermatology (1960), 1997-05, Vol.133 (5), p.654

Gibney, Mary Davis

1997

Volltextzugriff (PDF)

Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial

Journal of the American Academy of Dermatology, 2008, Vol.58 (1), p.106-115

2008

Volltextzugriff (PDF)

Alefacept for psoriasis

Seminars in cutaneous medicine and surgery, 2010-03, Vol.29 (1), p.53-55

2010

Volltextzugriff (PDF)

Analysis of the polymerase chain reaction in the detection of herpesvirus DNA from fixed and stained tissue sections

Archives of dermatology (1960), 1995-07, Vol.131 (7), p.805

1995

Volltextzugriff (PDF)

Anti–Interleukin-17 Monoclonal Antibody Ixekizumab in Chronic Plaque Psoriasis

The New England journal of medicine, 2012-03, Vol.366 (13), p.1190-1199

2012

Volltextzugriff (PDF)

Antibodies in the Treatment of Psoriasis: IL-12/23 p40 and IL-17a

Seminars in cutaneous medicine and surgery, 2016-06, Vol.35 (4 Suppl 4), p.S74-S77

Leonardi, Craig L

2016

Volltextzugriff (PDF)

Antibodies in the Treatment of Psoriasis: IL-12/23 p40 and IL-17a

Seminars in cutaneous medicine and surgery, 2016-06, Vol.35 (4S), p.S74

Leonardi, Craig L

2016

Volltextzugriff (PDF)

Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1)

Journal of the American Academy of Dermatology, 2015-07, Vol.73 (1), p.37-49

2015

Volltextzugriff (PDF)

Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: a meta-analysis of randomized controlled trials

JAMA : the journal of the American Medical Association, 2011-08, Vol.306 (8), p.864

2011

Volltextzugriff (PDF)

Basal cell carcinoma of the scrotum

Journal of the American Academy of Dermatology, 1992-04, Vol.26 (4), p.574-578

1992

Volltextzugriff (PDF)

Basal cell carcinoma of the scrotum : report of three cases and review of the literature

Journal of the American Academy of Dermatology, 1992-04, Vol.26 (4), p.574-578

1992

Volltextzugriff (PDF)

A boxed warning for inadequate psoriasis treatment

Cutis (New York, N.Y.), 2016-09, Vol.98 (3), p.206-207

2016

Volltextzugriff (PDF)

Brodalumab, an Anti–Interleukin-17–Receptor Antibody for Psoriasis

The New England journal of medicine, 2012-03, Vol.366 (13), p.1181-1189

2012

Volltextzugriff (PDF)

The burden of illness associated with psoriasis: cost of treatment with systemic therapy and phototherapy in the US

Current medical research and opinion, 2004-12, Vol.20 (12), p.1929-1936

2004

Volltextzugriff (PDF)

Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks from 2 phase 3, multicenter, randomized, double-blinded, placebo-controlled studies (CIMPASI-1 and CIMPASI-2)

Journal of the American Academy of Dermatology, 2018-08, Vol.79 (2), p.302-314.e6

2018

Volltextzugriff (PDF)

Clinical Efficacy of Efalizumab in Patients with Chronic Plaque Psoriasis: Results from Three Randomized Placebo-Controlled Phase III Trials: Part I

Journal of cutaneous medicine and surgery, 2005-12, Vol.9 (6), p.303-312

2005

Volltextzugriff (PDF)

Clinical efficacy of efalizumab in patients with chronic plaque psoriasis : Results from three randomized placebo-controlled. Phase III trials: Part I

Journal of cutaneous medicine and surgery, 2005-12, Vol.9 (6), p.303-312

2005

Volltextzugriff (PDF)

1 – 25 von 148

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(135)
Mit Volltextzugriff
(104)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(93)
Dermatology
(90)
Life Sciences & Biomedicine
(89)
Humans
(88)
Psoriasis - Drug Therapy
(56)
Psoriasis
(47)
Biological And Medical Sciences
(45)
Female
(45)
Male
(45)
Medical Sciences
(45)
Middle Aged
(38)
Adult
(36)
Treatment Outcome
(31)
Psoriasis. Parapsoriasis. Lichen
(27)
Severity Of Illness Index
(27)
Antibodies, Monoclonal - Therapeutic Use
(22)
Double-Blind Method
(21)
Aged
(18)
Antibodies, Monoclonal - Adverse Effects
(18)
Antibodies, Monoclonal - Administration & Dosage
(16)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

13883 Maintenance of response through 136 weeks of long-term continuous risankizumab treatment: An analysis of patients from UltIMMa-1 and UltIMMa-2

15350 Consistent scalp psoriasis clearance with mirikizumab maintenance treatment at 104 weeks in patients who had less than PASI 90 response at week 16: A phase 2 study analysis

15984 Psoriasis patients treated with ixekizumab were maintained longer on monotherapy compared with other biologics in real-world clinical practice settings: Results from IBM MarketScan databases

16007 Ixekizumab demonstrated longer medication persistence than other biologics in the treatment of psoriasis patients: Results from IBM MarketScan databases

A 52-week, open-label study of the efficacy and safety of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with chronic plaque psoriasis

Absence of Borrelia burgdorferi in patients with localized scleroderma (morphea)

Absence of human papillomavirus infection in cutaneous lichen planus

ACROKERATOELASTOIDOSIS OF COSTA

Acute Papulosquamous Eruption of the Extremities Demonstrating an Isomorphic Response

Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial

Alefacept for psoriasis

Analysis of the polymerase chain reaction in the detection of herpesvirus DNA from fixed and stained tissue sections

Anti–Interleukin-17 Monoclonal Antibody Ixekizumab in Chronic Plaque Psoriasis

Antibodies in the Treatment of Psoriasis: IL-12/23 p40 and IL-17a

Antibodies in the Treatment of Psoriasis: IL-12/23 p40 and IL-17a

Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1)

Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: a meta-analysis of randomized controlled trials

Basal cell carcinoma of the scrotum

Basal cell carcinoma of the scrotum : report of three cases and review of the literature

A boxed warning for inadequate psoriasis treatment

Brodalumab, an Anti–Interleukin-17–Receptor Antibody for Psoriasis

The burden of illness associated with psoriasis: cost of treatment with systemic therapy and phototherapy in the US

Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks from 2 phase 3, multicenter, randomized, double-blinded, placebo-controlled studies (CIMPASI-1 and CIMPASI-2)

Clinical Efficacy of Efalizumab in Patients with Chronic Plaque Psoriasis: Results from Three Randomized Placebo-Controlled Phase III Trials: Part I

Clinical efficacy of efalizumab in patients with chronic plaque psoriasis : Results from three randomized placebo-controlled. Phase III trials: Part I

Suchergebnisse filtern